Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine – results from a German cohort study

Hyperparathyroidism has been described in people living with HIV undergoing tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy (ART), but differences in calcium levels have never been investigated in detail. We aimed to compare the prevalence of hypocalcemia between patients with and without TDF-containing ART. The patients and methods were a retrospective cohort study in HIV-infected adult patients receiving dolutegravir and either abacavir (ABC)/lamivudine (3TC) or TDF/emtricitabine in a single center in Munich, Germany. Of 172 patients, 126 (73.3%) were male and the median age was 48.5 years (interquartile range 42–54). Average calcium levels were 2.24 (2.21–2.29) mmol/l and 2.21 (2.16–2.26) mmol/l (P < 0.001) with a prevalence of at least one episode of total calcium <2.12 mmol/l of 16.2 and 34.4% in the groups treated with ABC/3TC and TDF/emtricitabine, respectively (P = 0.006). TDF use was independently associated with the occurrence of albumin-corrected calcium levels of <2.12 mmol/l (odds ratio: 6.7 [1.3–35.6]; P = 0.025). Hypocalcemia seems to occur more often in TDF-treated patients. Further research into hypocalcemia with TDF and potential cardiovascular effects may be of benefit based on these findings.

[1]  L. Soldati,et al.  High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  M. Mace,et al.  Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels of Parathyroid Hormone In Vivo Through the FGF Receptor in Normocalcemia, But Not in Hypocalcemia , 2017, Calcified Tissue International.

[3]  Jueying Lin,et al.  Nephrolithiasis and Osteomalacia associated with adefovir-induced Fanconi syndrome in a patient with hepatitis B , 2017, BMC Nephrology.

[4]  M. Shlipak,et al.  Association of Tenofovir Use With Risk of Incident Heart Failure in HIV‐Infected Patients , 2017, Journal of the American Heart Association.

[5]  J. Gustafsson,et al.  Drug‐Mediated Gene Regulation of Vitamin D3 Metabolism in Primary Human Dermal Fibroblasts , 2017, Basic & clinical pharmacology & toxicology.

[6]  A. Conigrave.  The Calcium-Sensing Receptor and the Parathyroid: Past, Present, Future , 2016, Front. Physiol..

[7]  P. Grant,et al.  Tenofovir and bone health , 2016, Current opinion in HIV and AIDS.

[8]  J. Lugon,et al.  Tenofovir monotherapy for hepatitis B after 1 year does not produce renal dysfunction, but is associated with hyperparathyroidism not related to vitamin D , 2016, European journal of gastroenterology & hepatology.

[9]  Satyajit Das,et al.  Relationship between vitamin D, parathyroid hormone, bone mineral density, fracture and antiretroviral therapy in HIV patients. , 2014, Recent patents on anti-infective drug discovery.

[10]  C. Sabin,et al.  No association between vitamin D deficiency and parathyroid hormone, bone density and bone turnover in a large cohort of HIV-infected men on tenofovir , 2014, Journal of the International AIDS Society.

[11]  Xiaobin Han,et al.  Calcium regulates FGF-23 expression in bone. , 2013, Endocrinology.

[12]  S. Moreno,et al.  Secondary hyperparathyroidism in HIV‐infected patients: relationship with bone remodeling and response to vitamin D supplementation , 2012 .

[13]  F. Gutiérrez,et al.  Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. , 2012, AIDS research and human retroviruses.

[14]  Pocaterra Daria,et al.  Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy? , 2011 .

[15]  M. Seibel,et al.  Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. , 2011, Journal of clinical gastroenterology.

[16]  F. Post,et al.  Do nevirapine and efavirenz affect vitamin D homeostasis similarly? , 2011, AIDS.

[17]  Christopher H. Johnson,et al.  Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  E. Ricci,et al.  Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy? , 2011, AIDS.

[19]  A. Copas,et al.  Tenofovir-Linked Hyperparathyroidism Is Independently Associated With the Presence of Vitamin D Deficiency , 2010, Journal of acquired immune deficiency syndromes.

[20]  F. Ibrahim,et al.  Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase , 2010, AIDS.

[21]  T. Brown,et al.  Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D , 2010, Antiviral therapy.

[22]  L. M. Mansky,et al.  Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. , 2010, Biochemical and biophysical research communications.

[23]  Zoran Bursac,et al.  Purposeful selection of variables in logistic regression , 2008, Source Code for Biology and Medicine.

[24]  D. Shoback,et al.  Fanconi's Syndrome in HIV+ Adults: Report of Three Cases and Literature Review , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.